Theravance Biopharma
safety summary | Theravance Biopharma
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
28 of 44
Related slides by other companies
BenevolentAI
Investor Presentation
October 2022
ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI
Arbutus Biopharma
Results
November 2022
safety summary | Arbutus Biopharma
Erasca
Investor Presentation
November 2023
has been dosed in more than patients to date establishing its safety tolerability and preliminary in multiple indications | Erasca
Compass Therapeutics
Investor Presentation
May 2023
interim phase study summary compass | Compass Therapeutics
Other recent decks by Theravance Biopharma
See all presentations (5 decks)
Results
August 2023
Results
May 2023
Investor Conference
April 2023
Results
February 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights